This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Oxygen Biotherapeutics, Inc. ("Oxygen") (NASDAQ: OXBT) announced today the Company will be presenting at the 6
th Annual OneMedForum Emerging Company Finance Conference to be held at the Sir Francis Drake Hotel in San Francisco this week. Michael Jebsen, President and Chief Financial officer, will present a corporate overview and update on Wednesday, January 9
th at 9:40 am PST. A link to access the webcast of this presentation is available on the Investors tab of Oxygen’s website
The OneMedForum San Francisco conference, runs concurrently with the J.P. Morgan Annual Healthcare Conference. These conferences are widely attended by investors and corporate executives interested in partnering, licensing, collaborating or investing. Attendees typically include institutional investors, buy and sell-side analysts, high net worth individual investors, senior healthcare and life science executives looking for investment opportunities. The conference offers market insights, licensing opportunities, acquisitions, joint ventures and strategic partnership networking opportunities.
Additional information can be found via:
About Oxygen Biotherapeutics, Inc.
Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(TM)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at
Caution Regarding Forward-Looking Statements
This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include the expansion of development of Oxycyte and the timing of the introduction of this new product. The forward-looking statements are subject to a number of risks and uncertainties including matters beyond the company's control that could lead to delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current Form 10-Q filed on December 14, 2012, and our annual report on Form 10-K filed on July 24, 2012, as well as other filings with the SEC. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.